EVOLVE-T2D Trademark

Trademark Overview

On Wednesday, January 12, 2022, a trademark application was filed for EVOLVE-T2D with the United States Patent and Trademark Office. The USPTO has given the EVOLVE-T2D trademark a serial number of 97215494. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Tuesday, July 23, 2024. This trademark is owned by Eli Lilly and Company. The EVOLVE-T2D trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Medical and scientific research in the field of diabetes
evolve-t2d

General Information

Serial Number97215494
Word MarkEVOLVE-T2D
Filing DateWednesday, January 12, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateTuesday, July 23, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 13, 2023

Trademark Statements

Pseudo MarkEVOLVE-T TWO D; EVOLVE-T TO D
Goods and ServicesMedical and scientific research in the field of diabetes

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, January 19, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285
Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events

Event DateEvent Description
Tuesday, September 20, 2022ASSIGNED TO EXAMINER
Saturday, January 15, 2022NEW APPLICATION ENTERED
Wednesday, January 19, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, October 6, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, October 6, 2022NON-FINAL ACTION WRITTEN
Thursday, October 6, 2022NON-FINAL ACTION E-MAILED
Wednesday, April 5, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 6, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, June 13, 2023PUBLISHED FOR OPPOSITION
Wednesday, April 5, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, May 10, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 24, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 8, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 13, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, January 10, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, January 10, 2024SOU EXTENSION 1 FILED
Wednesday, January 10, 2024SOU EXTENSION 1 GRANTED
Tuesday, July 23, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, July 23, 2024SOU EXTENSION 2 FILED
Tuesday, July 23, 2024SOU EXTENSION 2 GRANTED
Wednesday, July 24, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 12, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

evolve diabetes field research scientific medical